Literature DB >> 8730628

A combined approach for the early detection of ovarian cancer in asymptomatic women.

G L Adonakis1, E Paraskevaidis, S Tsiga, K Seferiadis, D E Lolis.   

Abstract

The purpose of this study was to investigate the effectiveness of the combined procedure including pelvic examination and serum CA-125 determination, as a screening method for the early detection of ovarian cancer. In 2000 women over 45 years old, without any evidence of adnexal disease, pelvic examination and serum CA-125 determination were performed. When either the findings of the pelvic examination were ambiguous or positive, or the serum CA-125 level was > 35 U/ml, further investigation including ultrasonography and laparoscopy or laparotomy was done. Among 174 women with clinical findings of adnexal disease there were 15 (8.62%) who had serum CA-125 > 35 U/ml. Among 18 women with elevated serum CA-125 (> 35 U/ml) there were 15 women (83.33%) who had clinical findings of adnexal disease. In 15 women further investigation was suggestive of adnexal disease and surgical exploration revealed three cases of malignancy. One case of serious ovarian cystadenocarcinoma stage Ia, one case of borderline ovarian tumour and one case of metastatic carcinoma from the right kidney. The other 12 women had benign adnexal masses or pelvic endometriosis. In our study this combined approach had sensitivity 100%, specificity 99.70% and P.P.V. 22%. According to these data, the procedure could be a potential component of a strategy aimed to the early detection of ovarian cancer, regardless of the financial cost.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730628     DOI: 10.1016/0301-2115(95)02369-0

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  9 in total

1.  Screening for ovarian cancer: recommendation statement.

Authors: 
Journal:  Ann Fam Med       Date:  2004 May-Jun       Impact factor: 5.166

2.  Recommendations on routine screening pelvic examination: Canadian Task Force on Preventive Health Care adoption of the American College of Physicians guideline.

Authors:  Marcello Tonelli; Sarah Connor Gorber; Ainsley Moore; Brett D Thombs
Journal:  Can Fam Physician       Date:  2016-03       Impact factor: 3.275

3.  Concern is not based on evidence.

Authors:  Ainsley Moore
Journal:  Can Fam Physician       Date:  2016-09       Impact factor: 3.275

4.  Management of a suspicious adnexal mass: a clinical practice guideline.

Authors:  J E Dodge; A L Covens; C Lacchetti; L M Elit; T Le; M Devries-Aboud; M Fung-Kee-Fung
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

Review 5.  Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis.

Authors:  Hiroshi Kobayashi
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

6.  Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial.

Authors:  Edward E Partridge; Robert T Greenlee; Thomas L Riley; John Commins; Lawrence Ragard; Jian-Lun Xu; Saundra S Buys; Philip C Prorok; Mona N Fouad
Journal:  Obstet Gynecol       Date:  2013-01       Impact factor: 7.661

7.  Ovarian cancer screening practices of obstetricians and gynecologists in puerto rico.

Authors:  Gianni Rodríguez-Ayala; Josefina Romaguera; Mariel López; Ana P Ortiz
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411

8.  The when and how of the gynaecological examination: a survey among Norwegian general practitioners.

Authors:  Stefán Hjörleifsson; Bjørn Bjorvatn; Eivind Meland; Guri Rørtveit; Yngvild Hannestad; Gunnar Tschudi Bondevik
Journal:  Scand J Prim Health Care       Date:  2019-05-29       Impact factor: 2.581

Review 9.  Screening, epidemiology, molecular biology, and treatment strategies for endometriosis-associated ovarian cancer.

Authors:  Hiroshi Kobayashi
Journal:  Reprod Med Biol       Date:  2009-09-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.